The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.
The investigation is a prospective, single center, open label, single-arm study. Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA injection, the final of which will occur between 18 and 24 hours post-injection.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
5
Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
Inland Imaging
Spokane, Washington, United States
Mean Absorbed Dose (Gy) for the Whole Body
Time frame: 18-24 hours
Mean Absorbed Dose (Gy) for Critical Non-liver Organs
Time frame: 18-24 hours
Mean Activity (Bq) for the Whole Body
Time frame: 18-24 hours
Mean Activity (Bq) for Critical Non-liver Organs
Time frame: 18-24 hours
Effective Dose (Gy) for the Whole Body
Time frame: 18-24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.